UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry

Thoreau, F; Chudasama, V; (2021) Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chemical Biology 10.1039/d1cb00082a. (In press). Green open access

[thumbnail of Enabling the next steps in cancer immunotherapy from antibody based bispecifics to multispecifics with an evolving role for bioconjugation chemistry.pdf]
Preview
Text
Enabling the next steps in cancer immunotherapy from antibody based bispecifics to multispecifics with an evolving role for bioconjugation chemistry.pdf - Accepted Version

Download (3MB) | Preview

Abstract

In the last two decades, immunotherapy has established itself as one of the leading strategy for cancer treatment, as illustrated by the exponentially growing number of related clinical trials. This trend was, in part, prompted by the clinical success of both immune checkpoint modulation and immune cell engagement, to restore and/or stimulate the patient’s immune system’s ability to fight the disease. These strategies were sustained by progress in bispecific antibody production. However, despite the decisive progress made in the treatment of cancer, toxicity and resistance are still observed in some cases. In this review, we intitally provide an overview of the monoclonal and bispecific antibodies developed with the objective to restore immune system functions to treat cancer (cancer immunotherapy), either being through immune checkpoint modulation, immune cell engagement or a combination of both. Their production, design strategy and impact on the clinical trial landscape were also addressed. In the second part, the concept of multispecific antibody formats, notably MuTICEMs (Multispecific Targeted Immune Cell Engager & Modulator), as a possible answer to current immunotherapy limitations is investigated. We believe it could be the next step to take for the cancer immunotherapy research and expose why bioconjugation chemistry might play a key role in these future developments.

Type: Article
Title: Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry
Open access status: An open access version is available from UCL Discovery
DOI: 10.1039/d1cb00082a
Publisher version: https://doi.org/10.1039/D1CB00082A
Language: English
Additional information: © Royal Society of Chemistry 2021. This article is Open Access (http://creativecommons.org/licenses/by-nc/3.0/)
UCL classification: UCL
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences > Dept of Chemistry
URI: https://discovery.ucl.ac.uk/id/eprint/10138501
Downloads since deposit
36Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item